Varvara Mareyeva

Ms. Varvara Mareyeva


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DSDmitri Shchekochikhin
Dmitri Shchekochikhin
KCKristina Charaya
Kristina Charaya
ASAlexandra Shilova
Alexandra Shilova
ANAlexey Nesterov
Alexey Nesterov
EPEkaterina S. Pershina
Ekaterina S. Pershina
DMDenis MD
Denis MD
Background: Acute heart failure (AHF) is one of the leading causes of admissions to the emergency department (ED). There is a need to develop an easy-to-use score that can be used in the ED to risk-stratify patients with AHF and in hospitalization decisions regarding cardiac wards or intensive care units (ICUs). Methods: A retrospective observational study was conducted at a city hospital. The data from the presentation of AHF patients at the ED were collected. The combined primary endpoint included death from any cause during hospitalization or transfer to an intensive care unit (ICU) for using inotropes/vasopressors. Feature selection was performed using artificial intelligence. Results: From August 2020 to August 2021, 908 patients were enrolled (mean age: 71.6 ± 13 years; 500 (55.1%) men). We found significant predictors of in-hospital mortality and ICU transfers for inotrope/vasopressor use and built two models to assess the need for ICU admission of patients from the ED. The first model included SpO2 < 90%, QTc duration, prior diabetes mellitus and HF diagnosis, serum chloride concentration, respiratory rate and atrial fibrillation on admission, blood urea nitrogen (BUN) levels, and any implanted devices. The second model included left ventricular end-diastolic size, systolic blood pressure, pulse blood pressure, BUN levels, right atrium size, serum chloride, sodium and uric acid concentrations, prior loop diuretic use, and pulmonary artery systolic blood pressure. Conclusions: We developed two models that demonstrated a high negative predictive value, which allowed us to distinguish patients with low risk and determine patients who can be hospitalized and sent from the ED to the floor. These easy-to-use models can be used at the ED.

7 March 2023 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
VMVarvara Mareyeva
Varvara Mareyeva
AKAlesya Alexandrovna Klimenko
Alesya Alexandrovna Klimenko
NSN. A. Shostak
N. A. Shostak
Pulmonary hypertension and right heart dysfunction often complicate the course of chronic heart failure. At the same time, the addition of these pathological conditions significantly increases the frequency of hospitalizations and worsens survival prognosis. That is why the assessment of the unfavorable outcome’s risk in the group of such patients is extremely important. This problem draws an interest for a more detailed study, considering the fact that the most convenient, accessible and minimally invasive prognosis marker has still being searched for nowadays. In this review article, which is based on the analysis of literature over the past 20 years dedicated to the problem of pulmonary hypertension and chronic heart failure, right ventricular-arterial coupling, has been considered as a relatively new parameter and as an example of one of these prognostic markers. This parameter can be assessed by echocardiography examination and our article describes several options of calculating it, including one of the most popular and valuable ratio of tricuspidal anular plane systolic excursion to the systolic pulmonary artery pressure (TAPSE/sPAP).

25 September 2023 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Closed access
VMVarvara Mareyeva
Varvara Mareyeva
AKAlesya Alexandrovna Klimenko
Alesya Alexandrovna Klimenko
NSN. A. Shostak
N. A. Shostak
Pulmonary hypertension is a serious cardiovascular pathology, often complicating the course of heart failure (HF). Excessive pulmonary artery pressure increases right ventricular afterload and progressively leads to dysfunction, which is associated with adverse outcomes regardless of left ventricular ejection fraction. In this regard, more attention should be paid to determining the right ventricular condition. Currently, in order to assess the right heart function in patients with pulmonary hypertension and HF, the right ventricular (RV)-pulmonary arterial (PA) coupling, is increasingly being used. The conventional formula to calculate this parameter is the ratio of tricuspid annular plane systolic excursion (TAPSE) and pulmonary artery systolic pressure (PASP). This index has proven to be a powerful predictor of adverse outcomes. But this calculation method has a number of limitations and can lead to errors. It is extremely important to exclude or minimize any possible inaccuracies during prognostic assessment, which is why new researches of alternative RV-PA calculation options have been recently published. Such things as problems that can occur during TAPSE and PASP evaluation, ways of modifying the assessment of right heart’s functioning in patients with pulmonary hypertension and heart failure have been addressed. The value of new RV-PA alternative «surrogate» indexes has been discussed.

15 October 2023 in The Clinician
Verified
Journal Article
Open access
PDF file
VMVarvara Mareyeva
Varvara Mareyeva
AKAlesya Alexandrovna Klimenko
Alesya Alexandrovna Klimenko
Elina MoskaletsElina Moskalets
Elina Moskalets
PGP. A. Glazunov
P. A. Glazunov
NSN. A. Shostak
N. A. Shostak
EZE. V. Zhilyaev
E. V. Zhilyaev
Introduction. A clinical case of an 80-year-old patient with clinical and instrumental manifestations of amyloidosis caused by the deposition of non-mutant (“wild type”) transthyretin (Amyloidosis “wild type” TransThyRetin, ATTRwt) is described. A special feature of this case was the diagnosis of amyloidosis at the same time as the identification of symmetrical polyarthritis.Aim. To present an example of successful diagnosis and timely treatment of ATTRwt amyloidosis.Materials and methods. Male patient (80 years old) consulted a rheumatologist in an outpatient clinic with complaints of weakness and pain in the muscles of the upper and lower extremities, swelling and soreness of both wrist joints; with manifestations of multiple tunnel syndromes (ulnar canal, Guyon canals, bilateral carpal tunnel syndrome). In addition, the patient had a heart involvement which appeared as left ventricle hypertrophy, paroxysmal form of atrial fibrillation, chronic heart failure with preserved ejection fraction, intraventricular conduction defect and low QRS voltage. Due to the presence of cardiac manifestations along with neuropathy, transthyretinic amyloidosis was suspected.Results. Polyneuropathy was confirmed by the results of electroneuromyography. AL-amyloidosis (immunoglobulin Light chain Amyloidosis) is excluded due to the absence of monoclonal proteins in the blood. The diagnosis was confirmed by the results of scintigraphy with with labeled technetium-99m pyrophosphate. Intensive accumulation of radiopharmaceutical was detected in the myocardium of the left ventricle. The study also confirmed the presence of polyarthritis, manifested by increased accumulation, in the area of the I metatarsophalangeal joint on the left, both wrist, shoulder and knee joints. The hereditary nature of ATTR amyloidosis was excluded by the results of genetic analysis, which did not reveal mutations in the transthyretin gene. The singularity of this case was in development of a symmetrical polyarthritis during amyloidosis manifestation. Pathogenetic therapy with tafamidis was initiated. Arthritis regressed after starting treatment with methotrexate.Conclusion. Transthyretin amyloidosis is a chronic progressive life-threatening disease caused by the formation and deposition of transthyretin-derived amyloid fibrils. The variety of amyloid tropicity to various organs and tissues leads to it phenotypic heterogeneity, which makes it difficult to make a diagnosis on early stages. However, the detection of «red flags» symptoms signaling the presence of transthyretin amyloidosis can shorten the time before initiation of targeted treatment, contributing to the improvement of the patient’s quality of life.

15 October 2024 in The Clinician
Verified
Journal Article
Open access
PDF file
AKAlesya Alexandrovna Klimenko
Alesya Alexandrovna Klimenko
ABAleksandra Bogdanova
Aleksandra Bogdanova
VMVarvara Mareyeva
Varvara Mareyeva
Pulmonary Hypertension (PH) is a hemodynamic and pathophysiological condition characterized by an increase in mean pulmonary artery (PA) pressure by at least 20 mm Hg at rest, measured during right heart catheterization. One of the fastest and most accessible screening non-invasive diagnostic methods for assessing the likelihood of this condition is echocardiography, which is performed according to the standard transthoracic echocardiography protocol, focusing on visualizing and describing certain parameters that characterize function of heart right chambers. In patients with PH, structural changes in the heart right chambers can be observed, such as enlargement of the right atrium and right ventricle, changes in their geometric shape, thickening right ventricle wall, dilatation of the main PA and its branches, and the appearance of tricuspid regurgitation. Pulmonary artery pressure can be measured using either the velocity of the tricuspid regurgitant jet or the ratio of the time acceleration of flow in the outflow tract of the right ventricle to the ejection time (mean pressure in the PA), or the velocity of the pulmonary regurgitation jet (end-diastolic pressure in the PA). Classic parameters of the functional state of the right ventricle, as well as additional indicators of the evaluation of the right ventricular function, for example, the ratio of the amplitude of movement of the fibrous ring to systolic pressure in the PA, called the right ventriculoarterial coupling, should be evaluated only in expert centers providing care for patients with PH. Correct and timely diagnosis, clear dynamic monitoring of the patient’s condition play a crucial role in prescribing targeted treatment and predicting the disease course.

11 April 2026 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Closed access
VMVarvara Mareyeva
Varvara Mareyeva
AKAlesya Alexandrovna Klimenko
Alesya Alexandrovna Klimenko
Aim . To study the clinical phenotypes of the right ventricular-pulmonary artery coupling (RV-PA coupling) and prognostic features in patients with pulmonary hypertension associated with ischemic chronic heart failure (PH-iCHF). Material and methods. A total of 69 stable patients with PH-iCHF and different left ventricular ejection fractions (LVEF) were examined. PH was defined as an increase in systolic pulmonary artery pressure (sPAP) above 30 mm Hg according to transthoracic echocardiography. The probability of PH was compared to the number of confirmed PH cases. The prevalence of PH-iCHF among CHF patients was established. Correlation between RV-PA coupling and LVEF was assessed. Clinical phenotypes were based on RV-PA coupling values as the tricuspid annular plane systolic excursion (TAPSE) and sPAP ratio. Adverse outcomes such as all-cause mortality and hospitalizations due to CHF decompensation over a follow-up period of 13.2±0.9 months were analyzed. Results . PH-iCHF occurred in 3.3% of CHF cases. sPAP above 30 mm Hg corresponded to 34.8% of patients with high probability of PH. For every 10% increase in LVEF, there was a corresponding increase in RV-PA coupling by 0.096 mm/mmHg. Based on the severity of RV-PA dissociation, three clinical phenotypes were formed: severe (0.47 mm/mmHg). Severe RV-PA dissociation was more frequently characterized by significant clinical manifestations (lower limb edema in 53%, ascites in 21% of cases), poor functional state (PH functional class III in 79% of cases), low exercise tolerance (six-minute walk test distance 267.2±107.4 m) and prolonged hospital stays (9.9±4.9 bed-days). High probability of PH was present in 67% of cases with severe RV-PA dissociation. There was no difference in time-to-adverse-outcome across clinical phenotypes. Predictors of adverse prognosis included RV-PA coupling ≤0.47 and ≤0.28 mm/mmHg, sPAP ≥40 mmHg, TAPSE ≤18 mm, right atrial area ≥18 cm², and transverse diameter of right ventricle ≥3.5 cm. Conclusion . The RV-PA coupling provides additional characteristics of clinical and functional status and identifies early adverse outcomes in patients with PH-iCHF.